GlassScriptPhysician profile
Wen Liang
NPI 1023092020
$6,399.46
in general payments reported to CMS, 2019-2025
38 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $47.81 · 2021: $650 · 2022: $1,531 · 2023: $1,201 · 2024: $1,075 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.45 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $844.40 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $782.81 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $558.91 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $358.48 | 2021-2024 | |
| Amarin Pharma, INC. | $340.47 | 2019-2023 | |
| Mylan Specialty L.P. | $264.20 | 2022-2024 | Yupelri, Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.64 | 2021-2025 | |
| Pfizer INC. | $233.19 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $226.92 | 2023-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.62 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $209.77 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $208.41 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $203.12 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $202.69 | 2019-2025 | Rybelsus, Ozempic |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.